论文部分内容阅读
目的:探讨弥可保联合卡马西平治疗痛性糖尿病神经病变的临床疗效。方法:80例痛性糖尿病神经病变患者,分成观察组和对照组。对照组:盐酸丁咯地尔注射液治疗痛性糖尿病神经病变;观察组:弥可保联合卡马西平治疗痛性糖尿病神经病变。结果:观察组总有效率85.00%高于对照组62.50%,差异显著(P<0.05)。治疗后,观察组正中神经、腓总神经传导速度改善情况优于对照组,差异显著(P<0.05)。结论:弥可保联合卡马西平治疗痛性糖尿病神经病变患者疗效可靠。
Objective: To investigate the clinical efficacy of methycobarb combined with carbamazepine in the treatment of diabetic neuropathies. Methods: Eighty patients with painful diabetic neuropathy were divided into observation group and control group. Control group: Buflomedil hydrochloride injection for the treatment of painful diabetic neuropathy; Observation group: Miqibao combined with carbamazepine treatment of painful diabetic neuropathy. Results: The total effective rate in observation group was 85.00%, which was significantly higher than that in control group (62.50%) (P <0.05). After treatment, the median nerve of the observation group, the improvement of the common peroneal nerve conduction velocity was better than the control group, the difference was significant (P <0.05). Conclusions: Miqibao combined carbamazepine treatment of diabetic patients with neuropathy is effective.